Efficacy News and Research

RSS

Cephalon announces positive results from study of NUVIGIL in bipolar depression

Cephalon, Inc. has announced positive results from a phase two clinical trial of NUVIGIL(R) (armodafinil) Tablets [C-IV] as adjunctive therapy for treating major depressive disorder in adults with bipolar I disorder.

17 Mar 2009

Engineering flu vaccines

A new computerized method of testing could help world health officials better identify flu vaccines that are effective against multiple strains of the disease.

17 Mar 2009

Alba Therapeutics announces next clinical trial of lead compound, Larazotide Acetate

Alba Therapeutics Corporation announced today it will initiate further clinical studies for patients diagnosed with celiac disease with their lead compound, larazotide acetate.

17 Mar 2009

Sirion Therapeutics sNDA for Durezol to treat uveitis accepted for FDA review

Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) seeking market approval of Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% to treat endogenous anterior uveitis has been accepted for review.

16 Mar 2009

Helix BioPharma receives approval to start phase II study of topical interferon alpha-2b in low-grade cervical lesions

Helix BioPharma Corp. announced that it has received the necessary regulatory approvals in Germany to initiate its planned Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions.

16 Mar 2009

Healthpoint intiates phase II clinical trial to evaluate effectiveness of HP802-247 in venous leg ulcers

Healthpoint announced that it has initiated a Phase II clinical trial investigating the efficacy of HP802-247 in venous leg ulcers.

16 Mar 2009

First treatment for muscular dystrophy a step closer

Genetic researchers at Children's National Medical Center and the National Center of Neurology and Psychiatry in Tokyo published the results of the first successful application of "multiple exon-skipping" to curb the devastating effects of Duchenne muscular dystrophy in an animal larger than a mouse.

16 Mar 2009

Combo therapy restores T cell numbers in HIV-infected individuals

White blood cells known as CD4+ T cells are the main target of HIV.

16 Mar 2009

Hyperbaric therapy for autism shows potential

Hyperbaric treatment for children with autism has reportedly led to improvements in the condition, though previous studies were uncontrolled.

15 Mar 2009

The navel shown to be a safe and effective single access route for extracting kidneys

Successful surgery that leaves no scars has become the main objective of the most daring and innovative surgeons.

From Evident Corporation - Life Sciences 12 Mar 2009

Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study

Results of a Schering-Plough Corporation Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary endpoints of safety and tolerability.

12 Mar 2009

New investigational therapy for the treatment of bladder cancer

A team of researchers, led by Columbia University Medical Center faculty, has identified a new investigational therapy for the treatment of bladder cancer.

12 Mar 2009

Biothera receives approval to launch two lung cancer trials

German regulatory authorities have granted approval to Biothera to conduct two open label, multicenter, randomized Phase II clinical trials studying Imprime PGGÂ® administered in combination with monoclonal antibodies and chemotherapy in patients with non-small cell lung cancer (NSCLC), the company announced today.

12 Mar 2009

BioCis Pharma starts trial of novel topical drug for dermatology

BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun a new Phase IIa clinical testing of ProtoCure emulsion cream, the company's novel topical drug for dermatology.

12 Mar 2009

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.

11 Mar 2009

Systematic estimation of breast cancer risk appears justified in postmenopausal women

Screening for breast cancer risk in all postmenopausal women, using a combination of risk factors and breast density, can identify women at high risk of disease, according to systematic literature reviews and meta-analyses reported in the March 10 online issue of the Journal of the National Cancer Institute.

11 Mar 2009

Scientists discover key molecules that inhibit viral production

The research, led by Professor Donny Strosberg of Scripps Florida, was published on March 4, 2009, in the Journal of General Virology's advance, online edition, Papers in Press.

11 Mar 2009

Angiotech Pharmaceuticals announces positive results from Bio-Seal study

Angiotech Pharmaceuticals, Inc. has announced positive clinical study results for its Bio-Seal Lung Biopsy Tract Plug System at the Society of Interventional Radiologists Annual Scientific Meeting in San Diego, CA.

11 Mar 2009

Freezing kidney cancer - interventional cryoablation

Freezing kidney tumors - using a safe minimally invasive interventional radiology treatment that kills the cancer 100 percent effectively without surgery - should be the gold standard or first treatment option for all individuals with tumors that are 4 centimeters in size or smaller.

10 Mar 2009

Azaya Therapeutics selected for Nanotechnology Characterization Lab by National Cancer Institute

Azaya Therapeutics, Inc. has announced that it has been selected by the National Cancer Institute (NCI) for a research collaboration to study Azaya's lead cancer therapy, ATI - 1123.

10 Mar 2009